Aptamer-based multiplexed proteomic technology for biomarker discovery

L Gold, D Ayers, J Bertino, C Bock, A Bock, E Brody… - Nature …, 2010 - nature.com
L Gold, D Ayers, J Bertino, C Bock, A Bock, E Brody, J Carter, V Cunningham, A Dalby…
Nature Precedings, 2010nature.com
Interrogation of the human proteome in a highly multiplexed and efficient manner remains a
coveted and challenging goal in biology. We present a new aptamer-based proteomic
technology for biomarker discovery capable of simultaneously measuring thousands of
proteins from small sample volumes (15 [mu] L of serum or plasma). Our current assay
allows us to measure~ 800 proteins with very low limits of detection (1 pM average), 7 logs
of overall dynamic range, and 5% average coefficient of variation. This technology is …
Abstract
Interrogation of the human proteome in a highly multiplexed and efficient manner remains a coveted and challenging goal in biology. We present a new aptamer-based proteomic technology for biomarker discovery capable of simultaneously measuring thousands of proteins from small sample volumes (15 [mu]L of serum or plasma). Our current assay allows us to measure ~800 proteins with very low limits of detection (1 pM average), 7 logs of overall dynamic range, and 5% average coefficient of variation. This technology is enabled by a new generation of aptamers that contain chemically modified nucleotides, which greatly expand the physicochemical diversity of the large randomized nucleic acid libraries from which the aptamers are selected. Proteins in complex matrices such as plasma are measured with a process that transforms a signature of protein concentrations into a corresponding DNA aptamer concentration signature, which is then quantified with a DNA microarray. In essence, our assay takes advantage of the dual nature of aptamers as both folded binding entities with defined shapes and unique sequences recognizable by specific hybridization probes. To demonstrate the utility of our proteomics biomarker discovery technology, we applied it to a clinical study of chronic kidney disease (CKD). We identified two well known CKD biomarkers as well as an additional 58 potential CKD biomarkers. These results demonstrate the potential utility of our technology to discover unique protein signatures characteristic of various disease states. More generally, we describe a versatile and powerful tool that allows large-scale comparison of proteome profiles among discrete populations. This unbiased and highly multiplexed search engine will enable the discovery of novel biomarkers in a manner that is unencumbered by our incomplete knowledge of biology, thereby helping to advance the next generation of evidence-based medicine.
nature.com